InvestorsHub Logo
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Live Updating
profile icon
surf1944 Free
08/13/08 10:22 PM
profile icon
surf1944 Free
06/20/08 5:24 PM
profile icon
surf1944 Free
05/19/08 12:00 PM

Pharmaxis Ltd. (PXSL) RSS Feed

Followers
0
Posters
1
Posts (Today)
0
Posts (Total)
3
Created
05/19/08
Type
Free
Moderators
http://www.pharmaxis.com.au/ http://finance.yahoo.com/q/ks?s=PXSL Pharmaxis, Ltd. engages in the research, development, and commercialization of human therapeutic products for the diagnosis and treatment of chronic respiratory and inflammatory/autoimmune diseases primarily in Australia. The company's products candidates include Aridol, a proprietary dry powder formulation of mannitol, which has completed Phase III clinical trial and is used for the diagnosis and management of asthma, and chronic obstructive pulmonary disease; Bronchitol, which is under Phase III clinical trial for the treatment of chronic obstructive lung diseases, including cystic fibrosis, bronchiectasis, and chronic bronchitis; PXS25/64 is under pre-clinical toxicology studies for the prevention of inappropriate migration of immune cells from blood to surrounding tissue; and PXS74, a pre-clinical development candidate for the treatment of asthma. It also develops PXS2076 for the treatment of rheumatoid arthritis and neuropathic pain. The company was founded in 1998 as Praxis Pharmaceuticals Australia Pty, Ltd. and changed its name to Pharmaxis Pty, Ltd. in 2002. Further, it changed its name to Pharmaxis, Ltd. in 2003. Pharmaxis is headquartered in Frenchs Forest, Australia.
Volume:
Day Range:
Last Trade Time:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
PXSL Latest News
  • No Recent News Available for this company!
New Post